{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,6]],"date-time":"2026-09-06T00:07:16Z","timestamp":1788653236054,"version":"build-2803163510"},"reference-count":28,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2016,9,1]],"date-time":"2016-09-01T00:00:00Z","timestamp":1472688000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"Department of Science and Technology (DST, Govt. of India)"},{"name":"Department of Biotechnology (DBT, Govt. of India)"},{"name":"CSIR (Govt. of India)"},{"name":"Ministry of Chemicals and Fertilizers"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Chromatography B"],"published-print":{"date-parts":[[2016,9]]},"DOI":"10.1016\/j.jchromb.2016.07.042","type":"journal-article","created":{"date-parts":[[2016,7,27]],"date-time":"2016-07-27T07:11:08Z","timestamp":1469603468000},"page":"123-130","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":24,"special_numbering":"C","title":["Pharmacokinetics and bioavailability assessment of Miltefosine in rats using high performance liquid chromatography tandem mass spectrometry"],"prefix":"10.1016","volume":"1031","author":[{"given":"Guru R.","family":"Valicherla","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Priyanka","family":"Tripathi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandeep K.","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anees A.","family":"Syed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammed","family":"Riyazuddin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Athar","family":"Husain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deep","family":"Javia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kishan S.","family":"Italiya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prabhat R.","family":"Mishra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiaur R.","family":"Gayen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jchromb.2016.07.042_bib0005","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1038\/nrmicro1748","article-title":"Visceral leishmaniasis: what are the needs for diagnosis, treatment and control?","volume":"5","author":"Chappuis","year":"2007","journal-title":"Nat Rev. Microbiol"},{"key":"10.1016\/j.jchromb.2016.07.042_bib0010","unstructured":"Kala-Azar elimination programme: report of a WHO consultation of partners, Geneva, Switzerland, 10\u201311 February 2015, World Health Organization 2015."},{"key":"10.1016\/j.jchromb.2016.07.042_bib0015","unstructured":"World Health Organization http:\/\/www.who.int\/leishmaniasis\/en\/."},{"key":"10.1016\/j.jchromb.2016.07.042_bib0020","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1016\/S0169-4758(00)01692-6","article-title":"Leishmania-host-cell interaction: complexities and alternative views","volume":"16","author":"Rittig","year":"2000","journal-title":"Parasitol. Today"},{"key":"10.1016\/j.jchromb.2016.07.042_bib0025","first-page":"733","article-title":"Miltefosine in the treatment of leishmaniasis: clinical evidence for informed clinical risk management","volume":"3","author":"Sundar","year":"2007","journal-title":"Ther. Clin. Risk Manage."},{"key":"10.1016\/j.jchromb.2016.07.042_bib0030","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1128\/CMR.19.1.111-126.2006","article-title":"Drug resistance in leishmaniasis","volume":"19","author":"Croft","year":"2006","journal-title":"Clin. Microbiol. Rev."},{"key":"10.1016\/j.jchromb.2016.07.042_bib0035","doi-asserted-by":"crossref","first-page":"2576","DOI":"10.1093\/jac\/dks275","article-title":"Miltefosine: a review of its pharmacology and therapeutic efficacy in the treatment of leishmaniasis","volume":"67","author":"Dorlo","year":"2012","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.jchromb.2016.07.042_bib0040","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1056\/NEJMoa021556","article-title":"Oral miltefosine for Indian visceral leishmaniasis","volume":"347","author":"Sundar","year":"2002","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jchromb.2016.07.042_bib0045","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1186\/1745-6215-12-166","article-title":"A.M. Musa Safety and efficacy of miltefosine alone and in combination with sodium stibogluconate and liposomal amphotericin B for the treatment of primary visceral leishmaniasis in East Africa: study protocol for a randomized controlled trial","volume":"12","author":"Omollo","year":"2011","journal-title":"Trials"},{"key":"10.1016\/j.jchromb.2016.07.042_bib0050","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1086\/519690","article-title":"Phase 4 trial of miltefosine for the treatment of Indian visceral leishmaniasis","volume":"196","author":"Bhattacharya","year":"2007","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.jchromb.2016.07.042_bib0055","doi-asserted-by":"crossref","first-page":"2855","DOI":"10.1128\/AAC.00014-08","article-title":"Pharmacokinetics of miltefosine in Old World cutaneous leishmaniasis patients","volume":"52","author":"Dorlo","year":"2008","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.jchromb.2016.07.042_bib0060","doi-asserted-by":"crossref","first-page":"3864","DOI":"10.1128\/AAC.00292-12","article-title":"Optimal dosing of miltefosine in children and adults with visceral leishmaniasis","volume":"56","author":"Dorlo","year":"2012","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.jchromb.2016.07.042_bib0065","first-page":"406","article-title":"HPLC detection of miltefosine using an evaporative light scattering detector","volume":"61","author":"Lemke","year":"2006","journal-title":"Pharmazie"},{"key":"10.1016\/j.jchromb.2016.07.042_bib0070","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.jchromb.2008.02.005","article-title":"Development and validation of a quantitative assay for the measurement of miltefosine in human plasma by liquid chromatography-tandem mass spectrometry","volume":"865","author":"Dorlo","year":"2008","journal-title":"J. Chromatogr. B"},{"key":"10.1016\/j.jchromb.2016.07.042_bib0075","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.jchromb.2015.06.017","article-title":"Quantification of miltefosine in peripheral blood mononuclear cells by high-performance liquid chromatography-tandem mass spectrometry","volume":"998-999","author":"Kip","year":"2015","journal-title":"J. Chromatogr. B"},{"key":"10.1016\/j.jchromb.2016.07.042_bib0080","doi-asserted-by":"crossref","first-page":"2081","DOI":"10.1128\/AAC.02976-15","article-title":"Validation and clinical evaluation of a novel method to measure miltefosine in leishmaniasis patients using dried blood spot sample collection","volume":"60","author":"Kip","year":"2016","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.jchromb.2016.07.042_bib0085","doi-asserted-by":"crossref","first-page":"533","DOI":"10.4155\/bio.16.7","article-title":"LC-coupled ESI MS for quantification of miltefosine in human and hamster plasma","volume":"8","author":"Jaiswal","year":"2016","journal-title":"Bioanalysis"},{"key":"10.1016\/j.jchromb.2016.07.042_bib0090","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1007\/BF00685563","article-title":"Pharmacokinetic behavior and antineoplastic activity of liposomal hexadecylphosphocholine","volume":"34","author":"Kaufmann-Kolle","year":"1994","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.jchromb.2016.07.042_bib0095","series-title":"FDA Guidance for Industry: Bioanalytical Method Validation","year":"2013"},{"key":"10.1016\/j.jchromb.2016.07.042_bib0100","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1080\/10826076.2011.557463","article-title":"Development and validation of a stability-indicating hplc method for analysis of zidovudine (zdv) in bulk drug and in vitro release studies of tablets","volume":"34","author":"Mandloi","year":"2011","journal-title":"J. Liq. Chromatogr. Related Tech."},{"key":"10.1016\/j.jchromb.2016.07.042_bib0105","doi-asserted-by":"crossref","first-page":"2198","DOI":"10.1016\/j.jchromb.2009.01.003","article-title":"Validation of bioanalytical LC-MS\/MS assays: evaluation of matrix effects","volume":"877","author":"Van Eeckhaut","year":"2009","journal-title":"J. Chromatogr. B"},{"key":"10.1016\/j.jchromb.2016.07.042_bib0110","doi-asserted-by":"crossref","first-page":"3019","DOI":"10.1021\/ac020361s","article-title":"Strategies for the assessment of matrix effect in quantitative bioanalytical methods based on HPLC-MS\/MS","volume":"75","author":"Matuszewski","year":"2003","journal-title":"Anal. Chem."},{"key":"10.1016\/j.jchromb.2016.07.042_bib0115","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1023\/A:1018943613122","article-title":"Physiological parameters in laboratory animals and humans","volume":"10","author":"Davies","year":"1993","journal-title":"Pharm. Res."},{"key":"10.1016\/j.jchromb.2016.07.042_bib0120","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1007\/BF02535556","article-title":"Distribution and metabolism of hexadecylphosphocholine in mice","volume":"22","author":"Breiser","year":"1987","journal-title":"Lipids"},{"key":"10.1016\/j.jchromb.2016.07.042_bib0125","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1007\/BF00695989","article-title":"Distribution of hexadecylphosphocholine and octadecyl-methyl-glycero-3-phosphocholine in rat tissues during steady-state treatment","volume":"31","author":"Marschner","year":"1992","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.jchromb.2016.07.042_bib0130","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1016\/j.bcp.2005.11.008","article-title":"Modulation of intestinal barrier properties by miltefosine","volume":"71","author":"Menez","year":"2006","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.jchromb.2016.07.042_bib0135","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1007\/s11095-006-9170-7","article-title":"Intestinal absorption of miltefosine: contribution of passive paracellular transport","volume":"24","author":"Menez","year":"2007","journal-title":"Pharm. Res."},{"issue":"Suppl. 1","key":"10.1016\/j.jchromb.2016.07.042_bib0140","doi-asserted-by":"crossref","first-page":"S17","DOI":"10.1016\/j.trstmh.2006.02.010","article-title":"Development of miltefosine as an oral treatment for leishmaniasis","volume":"100","author":"Sindermann","year":"2006","journal-title":"Trans. R. Soc. Trop. Med. Hyg."}],"container-title":["Journal of Chromatography B"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1570023216305177?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1570023216305177?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,10]],"date-time":"2018-09-10T06:53:03Z","timestamp":1536562383000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1570023216305177"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,9]]},"references-count":28,"alternative-id":["S1570023216305177"],"URL":"https:\/\/doi.org\/10.1016\/j.jchromb.2016.07.042","relation":{},"ISSN":["1570-0232"],"issn-type":[{"value":"1570-0232","type":"print"}],"subject":[],"published":{"date-parts":[[2016,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pharmacokinetics and bioavailability assessment of Miltefosine in rats using high performance liquid chromatography tandem mass spectrometry","name":"articletitle","label":"Article Title"},{"value":"Journal of Chromatography B","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jchromb.2016.07.042","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}